Articles On Dimerix (ASX:DXB)
Title | Source | Codes | Date |
---|---|---|---|
Closing Bell: ASX dips on war tensions; fingers firmly crossed ahead of Nvidia’s latest earnings
ASX dips as energy stocks lead losses Global tensions weigh on markets, gold stocks rise China holds rates steady, Nvidia’s earnings later tonight The ASX slipped from Tuesday’s high, closing lower by 0.57% on Wednesday. Global worries... |
Stockhead | DXB | 1 day ago |
Closing Bell: ASX ends Friday in style; NoviqTech explodes 180pc
ASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance cools market optimism NoviqTech shares surge after securing blockchain funding The ASX rose by 0.74% on Friday, with 10 out of 11 sectors fi... |
Stockhead | DXB | 6 days ago |
Five ASX healthcare companies poised for game-changing catalysts
Several ASX healthcare companies have upcoming catalysts, which can be a focal point for healthcare investors Dimerix forecasts the second interim analysis of its ACTION 3 global phase III trial of DMX-200 to treat FSGS in around mid-CY25... |
Stockhead | DXB | 1 week ago |
Biocurious: No sweat as Botanix tackles the world’s third-biggest skin disorder
Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil... |
Stockhead | DXB | 1 week ago |
Closing Bell: Stocks, USD soar and Bitcoin hits record as Trump leads tight race
Stocks surge and US dollar jumps as Trump leads ASX rises amid tight US election race Bitcoin hits record as Trump-linked trades soar Stocks surged, Treasury yields soared, and the US dollar looked set for its biggest gain since March... |
Stockhead | DXB | 2 weeks ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | DXB | 2 weeks ago |
Closing Bell: Macquarie drags down bank stocks; Ironbark Zinc soars as Zelenski takes the chair
ASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decline Ironbark Zinc jumps 75% on new leadership The ASX kicked off November with a thud, sliding about 0.5%. This follows a tough session o... |
Stockhead | DXB | 2 weeks ago |
Market Highlights: US mega tech stocks crumble on earnings; oil stocks on watch as crude jumps 3pc
ASX set to open lower after Wall Street tech stocks slump Amazon soars on strong holiday sales forecast Roblox and Peloton shares surge while Robinhood drops The ASX is set to fall when the market resumes on Friday after a very rough da... |
Stockhead | DXB | 2 weeks ago |
Key findings could boost Dimerix’s rare kidney disease drug trial
PARASOL working group confirms eGFR as an approved surrogate endpoint for FDA approval of treatments for focal segmental glomerulosclerosis The working group also determined that proteinuria alone may also be suitable for FDA full approva... |
Stockhead | DXB | 3 weeks ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | DXB | 1 month ago |
The ASX stocks leading clinical trials in Australia
Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit... |
Stockhead | DXB | 2 months ago |
Closing Bell: ASX touches peak, gold miners shine, and vanadium stocks in the spotlight
ASX hits all-time high before retreating slightly Gold miners surge as prices near record high Hong Kong falls on weak China data; Yen rises The ASX briefly hit an all-time high on Monday before paring gains. At the close of the da... |
Stockhead | DXB | 2 months ago |
Insiders are buying up Pilbara Minerals shares. Should you?
The Pilbara Minerals Ltd (ASX: PLS) share price has soared an incredible 20% over the last week, recovering the ground that it lost during the first 10 days of September, as shown on the chart below. It may not come as a complete surp... |
Motley Fool | DXB | 2 months ago |
ASX Market Close: Uranium and Lithium stocks jump, as Wisetech breaks record | September 12, 2024
The ASX200 has closed up 1.1% at 8,075 points. The Aussie bourse followed Wall Street’s tech sector higher, despite US investors reducing expectations of an up-sized Fed rate cute next week. Back home, all sectors gained ground and the I... |
themarketonline.com.au | DXB | 2 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) enjoyed a convincing return to form this Thursday, rising enthusiastically after several days of stagnation. The ASX 200 clos... |
Motley Fool | DXB | 2 months ago |
Closing Bell: Uranium stocks go full turbo after Putin threat; Lithium’s theme still intact, says IGO
ASX climbs with tech, energy, and uranium stocks driving gains Uranium stocks surge as Putin hints at possible export limits Lithium miners rise on growing demand, while WiseTech hits a new record high The ASX took a leap on Thursday... |
Stockhead | DXB | 2 months ago |
ASX lithium shares could be set for a bull run if this 25% forecast is right
ASX lithium shares are bouncing on Thursday despite the lithium carbonate price trading at three-year lows and their peers in the materials sector lagging the market today. The S&P/ASX All Ordinaries Index (ASX: XAO) is up 0.75% whi... |
Motley Fool | DXB | 2 months ago |
Here's why ASX uranium shares are going on an explosive run today
ASX uranium shares are storming higher today. During the Thursday lunch hour, the All Ordinaries Index (ASX: XAO) is up a healthy 0.8%. And it's getting plenty of support from the uranium miners. Here's how these leading ASX uranium shares... |
Motley Fool | DXB | 2 months ago |
Why Dimerix, Paladin Energy, Pilbara Minerals, and Resolute Mining shares are storming higher today
The S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. In early afternoon trade, the benchmark index is up a sizeable 0.7% to 8,043.7 points. Four ASX shares that are rising more than most today are listed below. Here's... |
Motley Fool | DXB | 2 months ago |
Why is this ASX defence stock rocketing 23% today?
AML3D Ltd (ASX: AL3) shares are having a strong session on Thursday. In morning trade, the ASX defence stock is up 23% to 16 cents. Why is this ASX defence stock rocketing? Investors have been fighting to get hold of the 3D manufacturing so... |
Motley Fool | DXB | 2 months ago |
Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3
Dimerix Limited (ASX:DXB) has confirmed it’s begun recruiting adolescent kidney disease patients in Mexico, now that its ‘ACTION3‘ Phase 3 clinical trial location has been selected. Ages range from 12 to 17. HotCopper users were perusing... |
themarketonline.com.au | DXB | 2 months ago |
Closing Bell: ASX falls but lithium stocks rally big on China news; MinRes also jumps 17pc
ASX falls on Wednesday with banks dragging down market Lithium stocks surge on CATL suspension reports; MinRes hits new high Energy stocks struggle as Brent drops below US$70 The ASX was on the back foot on Wednesday, down by 0.3% w... |
Stockhead | DXB | 2 months ago |
Top brokers name 3 ASX shares to buy today
Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis... |
Motley Fool | DXB | 2 months ago |
Dimerix first patient completes Phase 3 trial and enters into long-term DMX-200 Open Label Extension study
First patient completes Phase 3 trial and joins Open Label Extension study for its kidney disease drug candidate DMX-200 All patients from its ACTION3 Phase 3 clinical trial are eligible to receive the drug under the OLE Results from study... |
Stockhead | DXB | 2 months ago |
Broker says this excellent ASX 200 tech stock can deliver market-beating returns
Now could be a good time to buy Life360 Inc (ASX: 360) shares. That's the view of analysts at Goldman Sachs, which think the ASX 200 tech stock could deliver market-beating returns over the next 12 months. What is the broker saying about th... |
Motley Fool | DXB | 2 months ago |
5 things to watch on the ASX 200 on Wednesday
On Tuesday, the S&P/ASX 200 Index (ASX: XJO) had a decent session and pushed higher. The benchmark index rose 0.3% to 8,011.9 points. Will the market be able to build on this on Wednesday? Here are five things to watch: ASX 200 expect... |
Motley Fool | DXB | 2 months ago |
ASX Market Close: Energy sector leads stocks higher as Index creeps towards record territory | September 10, 2024
The ASX200 closed up 0.3% at 8,012 points, just below its all time high set a few weeks ago. The local bourse climbed higher as both Commonwealth Bank and Macquarie broke share price records. The Energy sector surged nearly 1%, follow... |
themarketonline.com.au | DXB | 2 months ago |
Alive and Kicking: Pot stock Argent Biopharma aims to raise bar on epilepsy treatment
Argent Biopharma plans further trials of its cannabinoid-based epilepsy treatment Argent’s early research work suggests “improved safety profile alongside enhanced efficacy.” The first patient in Dimerix’s pivotal kidney trial enters open... |
Stockhead | DXB | 2 months ago |
Why Dimerix, Life360, S2 Resources, and SG Fleet shares are sinking today
In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 8,034.2 points. Four ASX shares that have failed to follow the market higher today... |
Motley Fool | DXB | 2 months ago |
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid... |
Stockhead | DXB | 2 months ago |
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment The ASX Healthcare Index (AS... |
Stockhead | DXB | 2 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | DXB | 3 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | DXB | 3 months ago |
ASX Market Close: IT sector leads market higher as Woodside falls on Scarborough cost hike | 23 July 2024
The ASX200 closed up half a percent at 7,971 points, as the market followed Wall Street’s strong lead. The IT sector lead the charge, up 1.62%, followed closely by Health Care 1.37% and Industrials 1.33%. The Energy sector lost 2% as the... |
themarketonline.com.au | DXB | 3 months ago |
ScoPo’s Powerplays: ASX health stocks rise amid renewed positive sentiment
ASX health stocks rise 2% in past five days as broader markets lift 0.6% Morgans upgrades disinfectant device maker Nanosonics after positive trading update Neuren receives rare paediatric disease designation from FDA for NNZ-2591 in Phel... |
Stockhead | DXB | 4 months ago |
Top 10 most traded ASX shares and US stocks in June
Mega ASX 200 iron ore shares BHP Group Ltd (ASX: BHP) and Fortescue Ltd (ASX: FMG) were the top two most traded ASX stocks last month among investors using the SelfWealth trading platform. Let's review the top 10. Top 10 most traded... |
Motley Fool | DXB | 4 months ago |
Investors’ sneak peek at biotech’s bright future
The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors Day one focus on new opportunities, finding the next blockbuster drug and re... |
Stockhead | DXB | 4 months ago |
Best 3 ASX 200 healthcare shares for price growth in FY24
In this article, we examine the best ASX 200 healthcare shares of FY24 based on share price growth. Here are the best performers, according to data from S & P Global Market Intelligence. The top 3 ASX 200 healthcare shares of FY2... |
Motley Fool | DXB | 4 months ago |
5 things to watch on the ASX 200 on Friday
On Thursday, the S&P/ASX 200 Index (ASX: XJO) had one of its best days of the year and stormed higher. The benchmark index rose 1.2% to 7,831.8 points. Will the market be able to build on this on Friday and end the week on a high? Her... |
Motley Fool | DXB | 4 months ago |
ASX Health Stocks: Which crypto high-flyer is investing in Singular Health?
Singular Health receives $1 million investment from prominent crypto figure Craig Sellars Adolescent recruitment into Dimerix’s ACTION3 Phase 3 trial to start after approval Lumos inks deals for test distinguishing viral from bacterial i... |
Stockhead | DXB | 4 months ago |
When $25 for board was daylight robbery
Women talk. But are we talking about the right things? Growing up in the 80s (I'm showing my age) my family didn't talk about finance, budgets or mortgages â I wish we had. I finished school with no responsibilities. I had no outgoings... |
Motley Fool | DXB | 4 months ago |
Why is the New Hope share price plunging today?
The New Hope Corp Ltd (ASX: NHC) share price is taking a tumble today. Shares in the S&P/ASX 200 Index (ASX: XJO) coal miner closed yesterday trading for $5.26. In early afternoon trade on Thursday, shares are swapping hands for $5.... |
Motley Fool | DXB | 4 months ago |
Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 7,818.3 points. Four ASX shares that have failed to follow the market higher today are l... |
Motley Fool | DXB | 4 months ago |
Why has this ASX mining stock exploded 128% in 2 days?
A little-known ASX mining stock is setting the bar high these past two days. Very high. At market close on Tuesday shares in Waratah Minerals Ltd (ASX: WTM) â previously known as Battery Minerals Limited â closed trading for 12.5 cents... |
Motley Fool | DXB | 4 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | DXB | 4 months ago |
If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!
Fancy grabbing a 917% one-year return from your ASX healthcare stock investment? Me too! The stock in question is clinical stage drug discovery and development company Dimerix Ltd (ASX: DXB) As you can likely guess by the phenomen... |
Motley Fool | DXB | 5 months ago |
2 ASX biotech shares that could be the next Telix Pharmaceuticals
Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)? You're not alone! The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to st... |
Motley Fool | DXB | 5 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | DXB | 5 months ago |
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks fall but Dimerix and Avita soar
ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis... |
Stockhead | DXB | 5 months ago |
Dimerix announces Middle East license agreement for DMX-200
Dimerix (ASX:DXB) has announced an exclusive license agreement with Taiba Middle East for the commercialisation of its candidate DMX-200. |
BiotechDispatch | DXB | 5 months ago |